title: Radioligands targeting P-glycoprotein and other drug efflux proteins at the blood-brain barrier.
abstract: Brain penetration of radiopharmaceuticals or therapeutic drugs may be restricted by adenosine triphosphate-binding cassette (ABC) transporters, such as P-glycoprotein (Pgp), breast cancer resistance protein (BCRP), or the multidrug resistance-associated proteins. These transporters are expressed in the luminal membrane of brain capillary endothelial cells forming the blood-brain barrier (BBB), where they actively efflux a wide range of chemically unrelated compounds from the brain back into the blood. Most efforts to visualize ABC transporters at the BBB with positron emission tomography have concentrated on Pgp. Pgp imaging probes can be classified as radiolabeled substrates or inhibitors. The radiolabeled substrates (R)-[(11) C]verapamil and [(11) C]-N-desmethyl-loperamide have been successfully used to assess Pgp function at the BBB of animals and humans. Radiolabeled Pgp inhibitors, such as [(11) C]tariquidar, [(11) C]elacridar, or [(11) C]laniquidar, were developed to measure Pgp expression levels at the BBB, which has so far remained unsuccessful as these probes were unexpectedly recognized at tracer concentrations by Pgp and BCRP as substrates resulting in low brain uptake. Studies on positron emission tomography tracers for other ABC transporters than Pgp (BCRP and multidrug resistance-associated proteins) are still in their infancy. It is hoped that the experience gained with the imaging of Pgp will be successfully translated to the development of radiotracers to visualize other ABC transporters.
authors.affiliation: Health & Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria.
authors.forename: Thomas
authors.initials: T
authors.lastname: Wanek
authors.forename: Severin
authors.initials: S
authors.lastname: Mairinger
authors.forename: Oliver
authors.initials: O
authors.lastname: Langer
mesh_terms: D018528:ATP-Binding Cassette Transporters / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000166:Acridines / Q000138:chemical synthesis* / Q000494:pharmacology; D000818:Animals; D001812:Blood-Brain Barrier / Q000000981:diagnostic imaging*; D002250:Carbon Radioisotopes / Q000737:chemistry; D006801:Humans; D007553:Isotope Labeling; D011804:Quinolines / Q000138:chemical synthesis* / Q000494:pharmacology; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000138:chemical synthesis* / Q000494:pharmacology; D044005:Tetrahydroisoquinolines / Q000138:chemical synthesis* / Q000494:pharmacology; D014700:Verapamil / Q000138:chemical synthesis* / Q000494:pharmacology
chemical_list: D018528:ATP-Binding Cassette Transporters; D000166:Acridines; D002250:Carbon Radioisotopes; D011804:Quinolines; D019275:Radiopharmaceuticals; D044005:Tetrahydroisoquinolines; D014700:Verapamil; C402343:tariquidar; C083501:Elacridar
keywords: (R)-[11C]verapamil; 11C; 18F; P-glycoprotein; [11C]-N-desmethyl-loperamide; adenosine-triphosphate binding cassette (ABC) transporter; blood-brain barrier; breast cancer resistance protein; multidrug resistance-associated proteins; positron emission tomography